Burrill Report: Innovating in the new austerity

Steve Burrill, CEO of life sciences venture capital and private equity firm Burrill and Co., made a large number of declarations, mostly negative, about the state of the industry at a BIO panel designed to drum up interest in buying his influential Burrill Report, which costs $519 for access to both the print and digital editions.

Burrill, considered to be something of an oracle in biotech circles, said that despite the pressures on the industry, biotech raised $63 billion overall in the past year. But he pointed to tender points for biotech including the increasingly murky landscapes for both patent protection and regulatory approval, and downward pressure on prices as part of a “new austerity.”